BCR-ABL (p210) Quantitation by PCR at Chughtai Lab

BCR-ABL (p210) Quantitation by PCR at Chughtai Lab

The BCR-ABL (p210) Quantitation by PCR at Chughtai Lab is a highly specialized molecular diagnostic test designed to detect and quantify the specific fusion gene transcript responsible for Chronic Myeloid Leukemia (CML) and a subset of Acute Lymphoblastic Leukemia (ALL) cases. This advanced molecular test utilizes Real-Time Quantitative Polymerase Chain Reaction (RT-qPCR) technology to measure the level of the BCR-ABL1 fusion transcript in a patient’s blood or bone marrow. The test targets the p210 transcript isoform, which is the hallmark of the Philadelphia chromosome (Ph), resulting from a reciprocal translocation between chromosomes 9 and 22, specifically designated as t(9;22)(q34.1;q11.2). This genetic rearrangement fuses the Abelson tyrosine kinase gene (ABL1) on chromosome 9 with the Breakpoint Cluster Region gene (BCR) on chromosome 22, creating an oncogene that produces a constitutively active tyrosine kinase protein. This abnormal protein drives uncontrolled cellular proliferation and survival in myeloid cells, leading to leukemia.

At Chughtai Lab, Pakistan’s leading diagnostic network, this test is performed under strict quality control measures in state-of-the-art molecular pathology departments. The clinical importance of BCR-ABL (p210) Quantitation cannot be overstated; it serves as the gold standard for diagnosing CML, establishing baseline transcript levels prior to initiating therapy, and monitoring the patient’s response to Tyrosine Kinase Inhibitors (TKIs) such as imatinib, nilotinib, dasatinib, and bosutinib. The diagnostic value of this test lies in its extreme sensitivity, capable of detecting one leukemia cell among hundreds of thousands of healthy cells. This level of precision allows hematologists and oncologists to assess treatment efficacy, detect minimal residual disease (MRD), identify early signs of therapeutic resistance, and make informed decisions regarding dosage adjustments or treatment modifications. By providing highly accurate quantitative data aligned with the International Scale (IS), Chughtai Lab ensures that patients receive world-class monitoring that directly influences clinical outcomes and long-term survival rates.

Clinical Procedure: What to Expect

Patient Preparation

Proper patient preparation is essential to ensure sample integrity and accurate molecular analysis. Patients undergoing the BCR-ABL (p210) Quantitation by PCR at Chughtai Lab should observe the following guidelines:

• No Fasting Required: There is no requirement to fast before this test. Patients may eat and drink normally prior to sample collection.
• Medication History: It is crucial to inform the laboratory staff and your treating physician of all current medications, particularly Tyrosine Kinase Inhibitors (TKIs) or other chemotherapeutic agents, as these directly affect transcript levels.
• Hydration: Staying well-hydrated is highly recommended, as it makes peripheral blood draw easier and more comfortable.
• Bone Marrow Collection Prep: If the test is being performed on a bone marrow aspirate rather than peripheral blood, follow specific preparation instructions provided by your hematologist, which may include temporary cessation of blood thinners.
• Identification and Paperwork: Bring your doctor’s prescription, previous BCR-ABL test reports, and official identification to the Chughtai Lab collection center to ensure accurate clinical correlation and tracking.

During the Procedure

The collection process for BCR-ABL (p210) Quantitation by PCR is straightforward but requires meticulous handling to prevent RNA degradation. The procedure involves the following steps:

• Sample Type: The test is most commonly performed on a peripheral blood sample, though bone marrow aspirate samples are also accepted depending on the physician’s request.
• Venipuncture: A phlebotomist will locate a suitable vein in your arm, cleanse the area with an antiseptic solution, and insert a sterile needle to draw blood.
• Specialized Collection Tubes: Blood is collected in specialized EDTA (purple-top) tubes. Because RNA is highly unstable and degrades rapidly, the sample must be handled with extreme care and transported to the molecular laboratory under controlled temperature conditions immediately.
• Duration: The blood draw takes less than five minutes. If a bone marrow aspirate is performed, it is conducted by a qualified hematologist in a clinical setting and takes approximately 15 to 30 minutes.
• Safety and Comfort: The venipuncture process involves minimal discomfort, similar to a brief prick. Chughtai Lab utilizes sterile, single-use vacuum collection systems to guarantee patient safety and prevent cross-contamination.
• Post-Collection Care: After the blood draw, pressure is applied to the puncture site, and a small bandage is applied. Patients can immediately resume their daily activities.

When is a BCR-ABL (p210) Quantitation by PCR Performed?

Diagnosis of Chronic Myeloid Leukemia (CML)

Physicians request the BCR-ABL (p210) Quantitation test when a patient presents with clinical symptoms or routine laboratory findings suggestive of Chronic Myeloid Leukemia. Common clinical indicators include an elevated white blood cell count (leukocytosis) with a full spectrum of myeloid precursors in the peripheral blood, unexplained splenomegaly, fatigue, night sweats, and weight loss. The detection of the p210 transcript confirms the diagnosis of CML and establishes the baseline molecular level necessary for monitoring future therapeutic response.

Monitoring Tyrosine Kinase Inhibitor (TKI) Therapy

Once a diagnosis of CML is established and the patient begins treatment with Tyrosine Kinase Inhibitors (TKIs), regular monitoring using quantitative PCR is mandatory. The test is typically performed at 3-month intervals during the first year of treatment and every 3 to 6 months thereafter. It measures the rate of decline in BCR-ABL1 transcripts, allowing clinicians to determine if the patient is meeting critical therapeutic milestones, such as achieving an Early Molecular Response (EMR) or a Major Molecular Response (MMR).

Detection of Minimal Residual Disease (MRD)

Minimal Residual Disease (MRD) refers to the small number of cancer cells that remain in the body during or after treatment, which cannot be detected by conventional microscopic examination of blood or bone marrow. The extreme sensitivity of the RT-qPCR assay performed at Chughtai Lab allows for the detection of trace amounts of the BCR-ABL1 transcript, providing crucial information about the depth of remission and helping to guide decisions regarding treatment continuation or potential discontinuation in eligible patients.

Assessment of Molecular Relapse

In patients who have achieved a stable molecular response, routine BCR-ABL quantitation is performed to monitor for molecular relapse. A sudden rise in transcript levels or the loss of a previously achieved Major Molecular Response (MMR) serves as an early warning sign of disease recurrence or the development of resistance mutations within the BCR-ABL1 kinase domain. Detecting molecular relapse early allows physicians to perform mutational analysis and switch to second- or third-generation TKIs before clinical or hematological relapse occurs.

Evaluation of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Approximately 25% to 30% of adult patients with Acute Lymphoblastic Leukemia (ALL) harbor the Philadelphia chromosome. While some present with the p190 transcript, others express the p210 transcript. Quantitative PCR for the p210 transcript is performed in these patients to confirm Ph+ status, stratify risk, guide the integration of TKIs into chemotherapy regimens, and monitor treatment response and post-transplant minimal residual disease.

What Does a BCR-ABL (p210) Quantitation by PCR Detect?

The BCR-ABL (p210) Quantitation by PCR at Chughtai Lab is designed to detect, analyze, and quantify several critical molecular parameters. The test provides a comprehensive assessment of the following clinical and molecular findings:

• Presence of BCR-ABL1 Transcripts: Confirms the qualitative presence of the t(9;22) translocation.
• Quantitative Transcript Copy Number: Measures the exact number of BCR-ABL1 fusion gene copies in the sample.
• Control Gene Expression: Quantifies a reference housekeeping gene (typically ABL1) to ensure the sample contains sufficient high-quality RNA for a valid test.
• BCR-ABL1 to Control Gene Ratio: Calculates the percentage of fusion transcripts relative to normal transcripts.
• International Scale (IS) Percentage: Standardizes the results to the International Scale, allowing direct comparison with global clinical trial data and guidelines.
• Baseline Transcript Levels: Establishes the pre-treatment molecular load of the leukemia.
• Early Molecular Response (EMR): Identifies if the BCR-ABL1 level is less than or equal to 10% at 3 months of therapy.
• Major Molecular Response (MMR / MR3.0): Detects a 3-log reduction in transcripts, equivalent to a BCR-ABL1 level of less than or equal to 0.1% on the International Scale.
• Deep Molecular Response (MR4.0): Detects a 4-log reduction, representing a BCR-ABL1 level of less than or equal to 0.01% IS.
• Deep Molecular Response (MR4.5): Detects a 4.5-log reduction, representing a BCR-ABL1 level of less than or equal to 0.0032% IS, indicating an extremely low tumor burden.
• Complete Molecular Response (CMR): Identifies when BCR-ABL1 transcripts are completely undetectable in a sample with high-quality RNA and adequate control gene copies.
• Molecular Relapse: Detects a significant increase in transcript levels (typically a 1-log or greater increase) in a patient who previously had stable low levels.
• Therapeutic Resistance: Suggests potential resistance to current TKI therapy when transcript levels fail to decline according to established clinical milestones.
• Sample Adequacy: Evaluates whether the collected specimen contains enough intact cells and high-quality RNA to yield a reliable diagnostic result.
• RNA Degradation: Identifies if the sample has degraded during transport, prompting a request for a repeat sample to ensure clinical accuracy.
• p210 Isoform Specificity: Specifically quantifies the e13a2 (b2a2) and e14a2 (b3a2) junctions of the p210 protein, distinguishing it from the p190 or p230 isoforms.
• Post-Transplant Chimerism Correlation: Assists in monitoring disease clearance following an allogeneic stem cell transplant.
• Treatment-Free Remission (TFR) Eligibility: Helps identify patients with sustained deep molecular response (MR4.0 or deeper for at least 2 years) who may be candidates for supervised treatment discontinuation.
• Early Recurrence During TFR: Monitors patients who have stopped TKI therapy to detect early molecular recurrence, allowing immediate resumption of treatment.
• Clonal Evolution Risk: Identifies patients with persistent high transcript levels who are at a higher risk of progressing from the chronic phase to the accelerated or blast phase of CML.

Turnaround Time and Report Access at Chughtai Lab

Chughtai Lab is committed to providing accurate and timely molecular diagnostic results. Because quantitative PCR is a highly complex molecular procedure involving RNA extraction, reverse transcription, and real-time amplification, the turnaround time for the BCR-ABL (p210) Quantitation test is typically 3 to 5 working days. This timeline ensures that the laboratory can perform necessary quality control checks, run duplicate samples if required, and have the results verified by a consultant molecular pathologist.

Patients and referring physicians can access reports easily through Chughtai Lab’s digital ecosystem. Once the report is finalized, an automated SMS notification containing a direct download link is sent to the patient’s registered mobile number. Reports can also be accessed and downloaded online through the official Chughtai Lab website portal or via the Chughtai Lab mobile application. Physical copies of the report can be collected from any Chughtai Lab collection center nationwide.

BCR-ABL (p210) Quantitation by PCR Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
BCR-ABL1 Transcript Detection	Not Detected (Negative)	Detected (Positive)
BCR-ABL1 / ABL1 Ratio (% IS)	0.00% (No fusion transcripts present)	> 0.00% (Indicates presence of Philadelphia chromosome-positive cells)
Control Gene (ABL1) Copy Number	> 10,000 copies (Indicates adequate sample quality)	< 10,000 copies (Inadequate sample; risk of false-negative results)
Early Molecular Response (EMR)	Not applicable in healthy individuals	> 10% IS at 3 months of TKI therapy (Indicates suboptimal response)
Major Molecular Response (MMR)	Not applicable in healthy individuals	Failure to achieve ≤ 0.1% IS at 12 months (Indicates delayed response or resistance)
Deep Molecular Response (MR4.5)	Not applicable in healthy individuals	Persistent detectable transcripts above 0.0032% IS (Limits eligibility for TFR)
Molecular Relapse Status	Stable undetectable or low levels	1-log or greater increase in transcript levels on consecutive tests (Indicates relapse)
Sample RNA Quality	Intact, high-quality RNA	Degraded RNA (Requires sample recollection due to pre-analytical issues)

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Chughtai Lab for BCR-ABL (p210) Quantitation by PCR?

• Experienced Healthcare Professionals: Chughtai Lab boasts a team of highly qualified consultant molecular pathologists and hematologists who oversee all molecular testing.
• Patient-Focused Care: The lab prioritizes patient comfort, offering clear instructions and compassionate care throughout the testing process.
• Quality Diagnostic Services: Operating under strict international quality control standards, Chughtai Lab ensures high accuracy and reproducibility of molecular results.
• Professional Reporting: Reports are structured clearly, providing results aligned with the International Scale (IS) for easy clinical interpretation by oncologists.
• Modern Diagnostic Approach: The molecular pathology department is equipped with state-of-the-art real-time PCR platforms capable of detecting low-copy-number transcripts.
• Comfortable Environment: All Chughtai Lab collection centers nationwide are designed to provide a clean, safe, and comfortable environment for patients.
• Convenient Location: With an extensive network of collection centers across Pakistan, patients can easily access testing facilities close to home.
• Commitment to Accurate Diagnosis: Chughtai Lab’s dedication to clinical excellence ensures that every PCR test undergoes rigorous validation before release.